Last reviewed · How we verify
NCT04382469
Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT
trial in COVID in 48 participants. Completed in 1 May 2020.
30 April 2020
Quick facts
| Lead sponsor | Alexandria University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 48 |
| Start date | 1 February 2020 |
| Primary completion | 30 April 2020 |
| Estimated completion | 1 May 2020 |
| Sites | 1 location across Egypt |
Conditions studied
- COVID — all drugs for COVID →
Sponsor
Alexandria University
Who can join
Eligibility, any sex, with COVID. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Corona virus disease 2019 (COVID-19) is a highly infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Purpose: To give initial experience about COVID-19 in Alexandria-Egypt describing radiological patterns of lung involvement, also surveying prevalence of co-morbid lung diseases and their effect on COVID-19 presentation. Methods: Retrospective study including 48 patients with positive polymerase chain reaction (PCR) test for COVID-19 during the period from February 2020 till May 2020 in Alexandria/Egypt. Full clinical and laboratory data are obtained. High resolution computed tomography (HRCT) findings are described. Serial follow up studies are done. Surveying co-morbid lung diseases done including tuberculosis (TB), interstitial lung diseases (ILDs), chronic obstructive lung disease (COPD), immune and vascular-related diseases. Prevalence rate is the predominant analysis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04382469
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID
Currently open trials in the same condition.
- NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
- NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
- NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
- NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
- NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting
Other Alexandria University trials
Trials by the same sponsor.
- NCT07517861 — Integrated Mental Health Nursing Program: Effects on Stigma, Cognitive Flexibility, and Clinical Readiness · NA · recruiting
- NCT07476482 — The Impact of a Shared Decision-Making Intervention on Intraoperative Patient Experience During Elective Cesarean Delive · NA · enrolling by invitation
- NCT07476209 — Sialendoscopy Versus Photobiomodulation in Prevention of Radiation Induced Xerostomia · NA · recruiting
- NCT07503626 — Optimization of Orthodontic Bracket Placement by Using Two Different Protocols of Digitally Aided Bonding · NA · recruiting
- NCT07522944 — AI-Guided Relaxation for Hemodialysis Anxiety · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04382469 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alexandria University
- Last refreshed: 12 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04382469.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing